Rimmyrah
Ranibizumab biosimilar developed by Qilu Pharmaceutical, development code QL1205. Reference product Lucentis.
Brands by market: Rimmyrah (EU) · Commercial partner or holder: Qilu Pharma Spain
FDAnot listed
EMAJan 2024authorised
CDSCOnot listed
EDEnot listed
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union · Rimmyrah
European Medicines Agency and European CommissionApprovedBrand
Rimmyrah
Holder or applicant
Qilu Pharma Spain S.L.
Pathway
Centralised (Article 10(4))
Approved
Jan 2024
Application or permission
EMEA/H/C/006055
Presentations
see SmPC
Source
S017
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Chronology
- EMAJan 2024Authorised by the European Commission
Sources
S017EMA, medicines data table (medicines-output-medicines-report_en.xlsx) Primary (regulator)
Planning ranibizumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.